• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Result of General Meeting

by chantal | Oct 20, 2026 | Latest News, Regulatory News

Preliminary Results for the year ended 30 April 2026

by chantal | Oct 9, 2026 | Latest News, Regulatory News

Atlantic crossing transforms outlook

by chantal | Oct 6, 2026 | Trinity Delta Reports

Publication of Circular, Notice of General Meeting and Proposed Share Consolidation

by chantal | Oct 2, 2026 | Latest News, Regulatory News

Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma

by chantal | Aug 19, 2026 | iSCIB1+, Latest News, Regulatory News

« Older Entries

Recent Posts

  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy